WFG Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$0 Sell
4
-754
-99% -$15.2K ﹤0.01% 1629
2017
Q1
$13K Sell
758
-600
-44% -$10.4K ﹤0.01% 1006
2016
Q4
$24K Sell
1,358
-32
-2% -$580 0.01% 894
2016
Q3
$29K Sell
1,390
-1,996
-59% -$49.5K 0.01% 847
2016
Q2
$91K Hold
3,386
0.02% 525
2016
Q1
$92K Buy
3,386
+14
+0.4% +$375 0.03% 491
2015
Q4
$98K Buy
3,372
+740
+28% +$20.5K 0.03% 473
2015
Q3
$71K Hold
2,632
0.02% 543
2015
Q2
$72K Sell
2,632
-16,408
-86% -$461K 0.02% 624
2015
Q1
$508K Sell
19,040
-3,406
-15% -$78.4K 0.14% 169
2014
Q4
$475K Sell
22,446
-4,650
-17% -$104K 0.1% 231
2014
Q3
$645K Buy
27,096
+196
+0.7% +$4.51K 0.12% 202
2014
Q2
$621K Sell
26,900
-260
-1% -$5.74K 0.12% 207
2014
Q1
$620K Sell
27,160
-7,670
-22% -$163K 0.12% 198
2013
Q4
$644K Buy
34,830
+840
+2% +$14.6K 0.09% 251
2013
Q3
$575K Buy
33,990
+230
+0.7% +$3.87K 0.09% 256
2013
Q2
$523K Buy
+33,760
New +$562K 0.09% 252

Other funds holding NVO

WFG Advisors's NVO Position: Q2 2017 in Review

WFG Advisors reduced its Novo Nordisk (NVO) stake by 99% in Q2 2017, selling an estimated $15.2K and leaving 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

WFG Advisors first reported a position in NVO in Q2 2013 and has held it in 17 quarters since. The position peaked at $645K in Q3 2014. 484 funds tracked by Wall St. Rank hold NVO as of Q2 2017.

  • WFG Advisors held 4 shares of Novo Nordisk worth $0 as of Q2 2017.
  • WFG Advisors sold 754 Novo Nordisk shares in Q2 2017, an estimated $15.2K.
  • Novo Nordisk made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1629 holding.
  • WFG Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 17 quarters since.
  • WFG Advisors's Novo Nordisk position peaked at $645K in Q3 2014.
  • 484 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.